Author

Martha D. Esajas

Observed names: Esajas, Martha D., M. D. Esajas, M. Esajas, Martha Esajas

Institutions: University Medical Center Groningen, University of Groningen

Observed institutions: University Medical Center Groningen, University of Groningen, Martini Ziekenhuis

ORCID: 0000-0003-0396-3120

Observed ORCID: 0000-0003-0396-3120

OpenAlex ID: A5021872017

Clinical Value of Routine Serum Squamous Cell Carcinoma Antigen in Follow-Up of Patients With Early-Stage Cervical Cancer

2001 · Martha D. Esajas, Jitze M. Duk, et al. · Journal of Clinical Oncology · 89

The Paget Trial: topical 5% imiquimod cream for noninvasive vulvar Paget disease

2022 · Michelle van der Linden, Colette L. van Hees, et al. · American Journal of Obstetrics and Gynecology · 35

P53‐specific T cell responses in patients with malignant and benign ovarian tumors: Implications for p53 based immunotherapy

2007 · Annechien Lambeck, Ninke Leffers, et al. · International Journal of Cancer · 34

Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial

2025 · Anneke L. Eerkens, Martha D. Esajas, et al. · Clinical Cancer Research · 21

The use of hydroxychloroquine as a systemic treatment in erosive lichen planus of the vulva and vagina

2021 · H. A. B. Vermeer, H. Rashid, et al. · British Journal of Dermatology · 21

Identification of a methylation panel as an alternative triage to detect CIN3+ in hrHPV-positive self-samples from the population-based cervical cancer screening programme

2023 · J. de Waard, A. Bhattacharya, et al. · Clinical Epigenetics · 12

Methylation Analysis to Detect CIN3+ in High-Risk Human Papillomavirus-Positive Self-Samples From the Population-Based Cervical Cancer Screening Program

2024 · Jolien de Waard, Arkajyoti Bhattacharya, et al. · Modern Pathology · 11

Juvenile and adult vulvar pemphigoid, an under recognized entity: Case series of fourteen patients

2021 · Hanan Rashid, J. Marja Oldhoff, et al. · JAAD Case Reports · 10

Preferences and Experiences Regarding the Use of the Self-Sampling Device in hrHPV Screening for Cervical Cancer

2021 · Marjolein Dieleman, Jolien de Waard, et al. · Patient · 8

Data from Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial

2025 · Anneke L. Eerkens, Martha D. Esajas, et al. · 1

Young women with (pre)malignant cervical disease in northern Netherlands: what characterises them – A population-based cohort study

2026 · Marjolein Dieleman, Karin M. Vermeulen, et al. · BMC Women s Health

Additional file 2 of Young women with (pre)malignant cervical disease in northern Netherlands: what characterises them – A population-based cohort study

2026 · Marjolein Dieleman, Karin M. Vermeulen, et al. · Figshare

Additional file 1 of Young women with (pre)malignant cervical disease in northern Netherlands: what characterises them – A population-based cohort study

2026 · Marjolein Dieleman, Karin M. Vermeulen, et al. · Figshare

Clinical validation of a three-marker methylation panel to detect CIN3+ in vaginal self-samples in the Dutch population-based screening programme

2025 · Jolien de Waard, Arkajyoti Bhattacharya, et al. · Clinical Epigenetics

Additional file 2 of Clinical validation of a three-marker methylation panel to detect CIN3+ in vaginal self-samples in the Dutch population-based screening programme

2025 · de Waard, Jolien, Bhattacharya, Arkajyoti, et al. · Figshare

Additional file 1 of Clinical validation of a three-marker methylation panel to detect CIN3+ in vaginal self-samples in the Dutch population-based screening programme

2025 · de Waard, Jolien, Bhattacharya, Arkajyoti, et al. · Figshare

Supplementary Table S3 from Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial

2025 · Anneke L. Eerkens, Martha D. Esajas, et al.

Supplementary Table S6 from Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial

2025 · Anneke L. Eerkens, Martha D. Esajas, et al.

Supplementary Table S1 from Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial

2025 · Anneke L. Eerkens, Martha D. Esajas, et al.

Supplementary Table S7 from Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial

2025 · Anneke L. Eerkens, Martha D. Esajas, et al.

Supplementary Table S2 from Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial

2025 · Anneke L. Eerkens, Martha D. Esajas, et al.

Supplementary Fig. S3 from Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial

2025 · Anneke L. Eerkens, Martha D. Esajas, et al.

Supplementary Table S5 from Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial

2025 · Anneke L. Eerkens, Martha D. Esajas, et al.

Supplementary Fig. S2 from Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial

2025 · Anneke L. Eerkens, Martha D. Esajas, et al.

Supplementary Fig. S4 from Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial

2025 · Anneke L. Eerkens, Martha D. Esajas, et al.

Works count: 29

Citation count: 241

H-index: 8

I10-index: 8